Last updated: 11/04/2018 08:29:00
A Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zanamivir 10 mg administered Twice Daily (20 mg/day) or 20 mg Twice Daily (40 mg/day) for 5 Days in the Treatment of Influenza A and B Viral Infections, and to Assess the Presence or Absence of Dose-Response Relationship of Zanamivir
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zanamivir 10 mg administered Twice Daily (20 mg/day) or 20 mg Twice Daily (40 mg/day) for 5 Days in the Treatment of Influenza A and B Viral Infections, and to Assess the Presence or Absence of Dose-Response Relationship of Zanamivir
Trial description: A Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zanamivir 10 mg administered Twice Daily (20 mg/day) or 20 mg Twice Daily (40 mg/day) for 5 Days in the Treatment of Influenza A and B Viral Infections, and to Assess the Presence or Absence of Dose-Response Relationship of Zanamivir
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Influenza, Human
Product
abacavir/lamivudine/zidovudine, zanamivir
Collaborators
Not applicable
Study date(s)
N/A to Invalid Date
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website